VC VCX Fundrise Innovation Fund, LLC Загрузка... : Бычьи и медвежьи мнения аналитиков

Long DXYZ VCX NSLR into Ant IPO

Author frames biotech software as his biggest AI bet but lists it as a speculative watchlist.

Buy CEF wrappers DXYZ/VCX/NSLR on Anthropic S-1

Author flags three low-liquidity vehicles as best asymmetric exposure to the OpenAI IPO.

Author lists four tickers without any directional commentary or position disclosure.

VCX 4x unlock, no borrow, IPO catalysts

Author frames the unlock as a bullish setup with no borrowable shares.

Author sarcastically flags these tickers as potentially ruinous trades without stating.

Открывайте короткие позиции по VCX, поскольку автор считает текущие рыночные условия близкими к.

VCX overvalued; lockup expiry to compress NAV.

Avoid VCX due to excessive valuation premiums and dilution risk relative to NAV.

Bearish view on VCX as alleged forced selling of key AI holdings after SPV statements points.

The tweet discusses a legal strategy involving Section 12(g) and DGCL demands against DXYZ.

Buy DXYZ/VCX at current market prices vs estimated NAVs.

The author notes lackluster Taiwan performance compared to the US and sarcastically lists.

Avoid VCX due to premium risk

VCX is a beneficiary of the structural trend of private companies going public earlier.

Anthropic IPO demand exceeds SpaceX IPO demand.

Stack Capital is highlighted as a high-performing.

VCX has a high borrow fee (800% rate), low float, and a share lockup period ending in September 2024. Its NAV is ~$20 vs. a share price ~$380. The lockup expiration will drastically increase the float, allowing restricted shareholders to sell, which should collapse the price toward NAV and has not been priced into October-dated options. Selling a call credit spread (Sell $70c / Buy $200c exp 10/17) profits if VCX is below $70 at expiration, which the author views as nearly guaranteed post-lockup. Early exercise on the short call (deemed irrational), a "miracle" business development that justifies a >3x NAV valuation, or option illiquidity causing poor fills.

Expect downside in VCX due to its extreme premium to the net asset value of its underlying.

Ben Miller states his job is to deploy capital into the best tech companies, not to manage where the stock trades. He explicitly says he is "not allowed to say where I think it should trade" and that trading volatility "has nothing to do with me." The CEO's mandate is executing the fund's strategy of providing democratized access to private tech. The extreme premium/discount to NAV is a market pricing phenomenon separate from the fund's operational execution. NEUTRAL because the speaker, who controls the fund's investments, explicitly refrains from expressing a view on the stock's direction or valuation, focusing solely on the foundational business thesis. Market sentiment detaches completely from NAV, impacting the fund's ability to raise capital or continue operations. Persistent extreme premium could attract regulatory scrutiny.

Citron Research questions VCX's financial math and highlights extreme borrowing costs.

Fundrise Growth Tech Fund experiences a massive price surge following its recent NYSE listing.

Citron Research has published a short report on $VCX, and the sponsor (Fundrise) filed to sell $23M of shares on the same day a critical report dropped, while most investors are locked up. This indicates the sponsor is exploiting a manufactured low-float, high-momentum situation to offload shares at inflated prices before the fundamental overvaluation corrects. The author views this as a clear short opportunity, expecting a ~90% collapse as the grift unravels, despite currently high short borrow fees. Extremely high borrow fee (~400% annualized, ~1% daily) could make holding the short position costly. A sustained short squeeze remains possible if buying pressure continues. The collapse thesis may take longer to materialize than expected.

VCX plummeted over 40% as the author criticizes speculative hype-driven investing in private.

Citron Research predicts a potential 93% decline in VCX price if its premium compresses.

Citron Research calls for an SEC investigation into potential undisclosed promotional payments.

Citron Research claims VCX is massively overvalued and highlights a history of SEC regulatory.

Citron Research highlights SEC charges against Fundrise for illegal paid solicitation practices.